Your browser doesn't support javascript.
loading
Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill, Sarah E; McGree, Michaela E; Weaver, Amy L; Cliby, William A; Langstraat, Carrie L.
Afiliação
  • Gill SE; Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA.
  • McGree ME; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Weaver AL; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  • Cliby WA; Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA.
  • Langstraat CL; Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA. Electronic address: langstraat.carrie@mayo.edu.
Gynecol Oncol ; 144(2): 266-273, 2017 Feb.
Article em En | MEDLINE | ID: mdl-27916269
ABSTRACT

OBJECTIVE:

To a) identify prognostic factors in patients with epithelial ovarian cancer treated with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), and b) compare post-surgical survival between patients treated with NACT/IDS for presumed unresectable disease and stage IIIC/IV patients who underwent suboptimal primary debulking surgery (PDS).

METHODS:

This was a retrospective study of consecutive stage IIIC or IV patients undergoing IDS after NACT at Mayo Clinic from January 2007 to December 2013. A subset of patients receiving NACT/IDS for the indication of unresectable disease were matched 11 on age and stage to a cohort of patients who underwent suboptimal PDS between 2003 and 2011. Hazard ratios and corresponding 95% confidence intervals were estimated from Cox proportional hazards models.

RESULTS:

We identified 87 patients treated with NACT/IDS the median OS and PFS following surgery was 2.4 and 1.0years, respectively. Factors associated with significantly worse OS were older age (adjusted HR 1.60 per 10-year increase in age, 95% CI 1.18, 2.16) and elevated CA-125 before IDS (adjusted HR 2.30 for CA-125 >35U/mL, 95% CI 1.25, 4.23). Number of adjuvant chemotherapy cycles administered did not have a significant effect on survival. In the matched cohort analysis of presumed unresectable cases undergoing NACT/IDS vs suboptimal PDS cases (n=45 each), the NACT/IDS group had a significant OS advantage (HR 0.53; 95% CI 0.32, 0.88), and fewer patients experienced a 30-day postoperative Accordion grade 3/4 complication (11% vs 36%, P=0.01).

CONCLUSIONS:

Younger age and normalization of CA-125 prior to IDS are associated with improved survival with NACT/IDS. For primary EOC where resection to residual disease of 1cm or less is unlikely, NACT/IDS is associated with improved survival and reduced perioperative morbidity compared to PDS. As these patients are likely best served by NACT/IDS, more reliable predictors of resectability would be valuable.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Epiteliais e Glandulares / Procedimentos Cirúrgicos de Citorredução Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Epiteliais e Glandulares / Procedimentos Cirúrgicos de Citorredução Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos